Share Price | Cresanto Global Limited Stock Analysis & Recommendation

Q: Should I buy, sell or hold Cresanto Global Limited?

Based on the current situation of Cresanto Global Limited, it would be advisable to consider selling your shares. The company has a negative book value and exhibits weak long-term fundamental strength, which is concerning. Additionally, the lack of growth in net sales and operating profit over the past five years indicates poor performance. The high debt levels, reflected in a debt-to-equity ratio of 0, further complicate the financial outlook. With flat results reported recently and a negative EBITDA, the stock appears to be trading at a higher risk compared to its historical valuations. Given that the stock has generated no returns over the past year while profits have declined, it may be prudent to look for better investment opportunities elsewhere.

Q: Why is Cresanto Global Limited falling/rising?

As of 20-Feb, Cresanto Global Limited's stock price is rising. The current price is Rs. 4.22, which is a new 52-week high reached today. The stock has outperformed its sector by 5.18%, indicating strong relative performance. Additionally, Cresanto Global is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a positive trend in its price movement. There has also been a significant increase in investor participation, with delivery volume rising by 2,974,900% compared to the 5-day average. This surge in trading activity reflects growing interest in the stock. Overall, these factors contribute to the upward movement in Cresanto Global Limited's stock price.

52-Week High: Rs.4.43 hit today

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1 (400.00%) Volume

Shareholding (Dec 2025)

FII

0.00%

Held by 0 FIIs

DII

0.96%

Held by 0 DIIs

Promoter

32.27%

When is the next results date for Raymed Labs?

26-May-2025

No Upcoming Board Meetings

Should I buy, sell or hold Cresanto Global Limited?

14-Feb-2026

Why is Cresanto Global Limited falling/rising?

20-Feb-2026

As of 20-Feb, Cresanto Global Limited's stock price has reached Rs. 4.22, a new 52-week high, and has outperformed its sector by 5.18%. The stock is trading above all major moving averages, indicating a positive trend, and has seen a significant increase in investor participation.

View full answer

Which are the latest news on Cresanto Global?

22-Feb-2026

Cresanto Global Limited Downgraded to Sell Amid Mixed Technicals and Weak Fundamentals
Cresanto Global is Rated Sell

Compare Cresanto Global with Similar Stocks

Fabino Enter Triochem Product MPS Pharmaa

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 0% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at 0 times

Flat results in Dec 25

Risky - Negative EBITDA

Underperformed the market in the last 1 year

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 2 Cr (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.00

Return on Equity

7.48%

Price to Book

-0.75

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

0 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

127.18%

4 Years

0.0%

5 Years

0.0%

Cresanto Global for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Cresanto Global Limited Hits New 52-Week High at Rs.4.43

Cresanto Global Limited, a player in the Pharmaceuticals & Biotechnology sector, achieved a significant milestone today by reaching a new 52-week high of Rs.4.43. This marks a notable moment in the stock’s recent performance, reflecting strong momentum amid a mixed market backdrop.

Read full news article

Cresanto Global Limited Downgraded to Sell Amid Mixed Technicals and Weak Fundamentals

Cresanto Global Limited, a player in the Pharmaceuticals & Biotechnology sector, has been assigned a Sell rating with a Mojo Score of 40.0, marking its first formal grade after previously being ungraded. This downgrade reflects a complex interplay of improved technical indicators contrasted by weak financial fundamentals and valuation concerns, prompting a cautious stance among investors.

Read full news article

Cresanto Global is Rated Sell

Cresanto Global is rated Sell by MarketsMOJO, with this rating last updated on 12 Nov 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 December 2025, providing investors with the latest insights into its fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Announcements

Board Meeting Outcome for Meeting Held On 23Rd February 2026

23-Feb-2026 | Source : BSE

Please find the attached Outcome of Board Meeting.

Announcement under Regulation 30 (LODR)-Newspaper Publication

06-Feb-2026 | Source : BSE

Please find the attached Newspaper Intimation for the publication of December 2025 quarter financial results.

Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

05-Feb-2026 | Source : BSE

Please find the attached Resignation letter of Company Secretary and Compliance Officer

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.96%

ROCE (avg)

-2.19%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.79

EV to EBIT

-1.89

EV to EBITDA

-1.89

EV to Capital Employed

-0.79

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bullish

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Nishant N Bajaj (9.05%)

Highest Public shareholder

Amzel Limited (7.02%)

Individual Investors Holdings

44.15%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 64.00% vs -1,150.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.11",
          "val2": "-0.26",
          "chgp": "57.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.09",
          "val2": "-0.25",
          "chgp": "64.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Cresanto Global"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Cresanto Global"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "alert": "No Annual Results declared by Cresanto Global"
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.11

-0.26

57.69%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

-0.09

-0.25

64.00%

Operating Profit Margin (Excl OI)

0.00%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Standalone Net Profit

YoY Growth in quarter ended Dec 2025 is 64.00% vs -1,150.00% in Dec 2024

All Quarterly Results

Company CV

About Cresanto Global Limited

Cresanto Global Limited

Micro Cap

Pharmaceuticals & Biotechnology

Raymed Labs Ltd is engaged in the manufacturing of pharmaceutical products and injectables.The product range of the company includes RAMPICILLIN - Ampicillin, a semisynthetic penicillin.RAMPICLOX - Equal quantities of Ampicillin and Cloxacillin.RAMPIMOX - Equal quantities of Amoxycillin and Cloxacillin.RAMYKACIN - Amikacin Sulphate.OXYTETRACYCLINE - The most common Antibiotic in Veterinary Practice.RAMYFENAC-Diclofenac Sodium. It is a potent non steroidal Anti-inflammatory, Analgesic & Antipyretic for human use.RAMAMINE- Chlorpheniramine Maleate. The most potent & effective Anti-histaminic for veterinary use.RAMYDEX-Dexamethasone Sodium Phosphate. Anti-inflammatory, Anti-allergic, Gluco-corticoid adjuvant with Antibiotic therapy.RAMYCIN-Gentamycin Sulphate.RAMYPINE - Atropin Sulphate. The drug has anticholenergic effect in veterinary use.RAMYCHLOR - Chloramphenicol.REALOPAR - Paracetamol.RAYVIL - Pheniramine Maleate.RAMALGIN-P - Phenylbutazone and Analgin with Lignocaine: A unique combination of highly effective analgesic, antispasmodic, anti-inflammatory & Antipyretic for veterinary use.RAMYSCAB - Sulphur with Benzyl Benzoate in Lidocaine base: An ideal treatment of Scabies & other dermal problems in animals.RAMYVIT PLEX - Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B12 with Liver Extract: crude injection and ideal treatment of Scabies & other dermal problems in animals.

Company Coordinates

Company Details

103 Emperor 1 Sector 93A, Supertech Emerald Court Noida Uttar Pradesh : 201304

Tel: 91-0120-2426900/9412700300

http://www.raymedlabs.com

raymedlabs@rediffmail.com

Registrar Details

Beetal Financial & Computer Services (P) Ltd , Beetal House , 99 Mandangir, 3rd Floor, Behind Local Shopping Centre, Near Dada Harsukhdas Mandir, New Delhi